Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ: ME )

1.770 +0.210 (+13.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 460,364
Open 1.560
Bid (Size) 1.690 (1)
Ask (Size) 1.750 (8)
Prev. Close 1.560
Today's Range 1.480 - 1.820
52wk Range 1.340 - 12.76
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
From 23andMe, Inc.
Via GlobeNewswire
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
-50.14%
-50.14%
1 Month
-31.13%
-31.13%
3 Month
-51.37%
-51.37%
6 Month
-70.92%
-70.92%
1 Year
-82.35%
-82.35%

More News

Read More
Trump's Metal Tariffs Set Stage For US Steel ETF Gains
Via Benzinga
Topics ETFs Government Stocks
Exposures Political US Equities
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For 23andMe Holding
Via Benzinga
23andMe Launches New Genetic Report on Osteoporosis
From 23andMe, Inc.
Via GlobeNewswire
23andMe Special Committee Announces Exploration of Strategic Alternatives
From 23andMe, Inc.
Via GlobeNewswire
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Deal Dispatch: Lovely Day To Sell Guinness? Plus, 23andMe To Rid Lineage Of Lemonaid
Via Benzinga
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
From 23andMe, Inc.
Via GlobeNewswire
Want $500 of Reliable Dividend Income in 2025? Invest $5,040 in These 3 Ultra-High-Yield Stocks.
Via The Motley Fool
The Shake-Up at Intel
Via The Motley Fool
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
From 23andMe, Inc.
Via GlobeNewswire
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
Via Benzinga
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
From 23andMe, Inc.
Via GlobeNewswire
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe to Report Q2 FY2025 Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Regains Compliance With Nasdaq Listing Requirements
From 23andMe, Inc.
Via GlobeNewswire
23andMe Appoints Three New Independent Directors to Board
From 23andMe, Inc.
Via GlobeNewswire
ASML's Latest Chapter in the Semiconductor Story
Via The Motley Fool
23andMe Introduces New Feature Helping African Americans Trace Their Roots to Post Slavery Communities in the South
From 23andMe, Inc.
Via GlobeNewswire
Author Alok Sama on OpenAI, Bubbles, and When to Sell
Via The Motley Fool
23andMe Announces Completion of 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
23andMe Announces 1-for-20 Reverse Stock Split
From 23andMe, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.